Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Minor: Lunsekimig · Chronic Obstructive Pulmonary Disease (COPD) Trial sites expanded: 8 → 16 locations SanofiPhase 3 NCT07793409
  2. Minor: EYE201/MK-8748 · Macular Degeneration (MK-8748-003) Trial sites expanded: 71 → 121 locations EyeBiotech Ltd.Phase 2/3 NCT07496567
  3. Minor: Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants Trial sites expanded: 8 → 20 locations Hoffmann-La RochePhase 3 NCT07827599
  4. Minor: SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) Trial sites expanded: 61 → 75 locations Nuvation Bio Inc.Phase 3 NCT05303519
  5. Minor: ALKS 2680 · Narcolepsy Type 2 Trial sites expanded: 44 → 61 locations Alkermes, Inc.Phase 3 NCT07502443
  6. Minor: EloraTZP · Obesity Without Type 2 Diabetes Trial sites expanded: 155 → 161 locations Eli Lilly and CompanyPhase 3 NCT07881432
  7. Minor: Sacituzumab Tirumotecan (Sac-TMT, MK-2870) · Breast Cancer (MK-2870-032) Trial sites expanded: 335 → 338 locations Merck Sharp & Dohme LLCPhase 3 NCT06966700
  8. Minor: Sacituzumab Tirumotecan (Sac-TMT, MK-2870) · Urothelial Cancer (MK-2870-031) Trial sites expanded: 111 → 117 locations Merck Sharp & Dohme LLCPhase 3 NCT07419295
  9. Minor: ALKS 2680 · Narcolepsy Type 1 Trial sites expanded: 42 → 66 locations Alkermes, Inc.Phase 3 NCT07455383
  10. Minor: GB-0895 Adjunctive Therapy in Adults and · Severe Uncontrolled Asthma (SOLAIRIA-2) Trial sites expanded: 158 → 166 locations Generate BiomedicinesPhase 3 NCT07359846
  11. Minor: Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD) Trial sites expanded: 50 → 56 locations Airway Therapeutics, Inc.Phase 2/3 NCT06897839
  12. Minor: EYE201/MK-8748 · Macular Degeneration (MK-8748-002) Trial sites expanded: 132 → 148 locations EyeBiotech Ltd.Phase 2/3 NCT07440225
  13. Minor: New Formulation of Oral Cladribine Compared With Placebo · Generalized Myasthenia Gravis (MyClad) Trial sites expanded: 153 → 159 locations Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyPhase 3 NCT06463587
  14. Minor: Canvuparatide Compared With Placebo · Hypoparathyroidism Trial sites expanded: 22 → 28 locations MBX BiosciencesPhase 3 NCT07699471
  15. Minor: Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) Trial sites expanded: 168 → 174 locations Novartis PharmaceuticalsPhase 3 NCT07357727
  16. Minor: Xywav Expanded Dosing vs Placebo · Narcolepsy or IH Trial sites expanded: 15 → 27 locations Jazz PharmaceuticalsPhase 3 NCT07625280
  17. Minor: ALKS 2680 · Narcolepsy Type 1 (Brilliance NT1 - 304) Trial sites expanded: 20 → 53 locations Alkermes, Inc.Phase 3 NCT07540897
  18. Minor: Outcomes of Pemvidutide in MASH Trial sites expanded: 9 → 62 locations Altimmune, Inc.Phase 3 NCT07795164
  19. Minor: Efimosfermin Compared With Placebo · Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) Trial sites expanded: 35 → 39 locations GlaxoSmithKlinePhase 3 NCT07704892
  20. Minor: BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer Trial sites expanded: 52 → 77 locations BioNTech SEPhase 3 NCT07365995
  21. Minor: Fenfluramine Hydrochloride in Rett Syndrome Trial sites expanded: 40 → 46 locations UCB BIOSCIENCES, Inc.Phase 3 NCT07503444
  22. Minor: Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections · Multiple Myeloma Trial sites expanded: 65 → 68 locations TakedaPhase 3 NCT06980480
  23. Minor: Efimosfermin Alfa Compared With Placebo · Alcohol-related Liver Disease (ALD) Trial sites expanded: 13 → 17 locations GlaxoSmithKlinePhase 2 NCT07791043
  24. Minor: Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy · HER2-positive Breast Cancer Trial sites expanded: 53 → 60 locations Jazz PharmaceuticalsPhase 2 NCT07102381
  25. Minor: PIPE 791 · Idiopathic Pulmonary Fibrosis Trial sites expanded: 108 → 111 locations Contineum TherapeuticsPhase 2 NCT07284459